Blog
    Regulatory UpdateFor PhysiciansAugust 14, 2026

    Peptide FDA regulatory status and FAERS safety signals

    Review FDA Category 2 compounding status for BPC-157 and TB-500, plus emerging FAERS safety signals for GLP-1 RAs including NAION and pulmonary aspiration.

    Clinical Question

    What is the current FDA regulatory status, compounding eligibility, and safety profile of frequently utilized therapeutic peptides, and what emerging safety signals are reported in postmarketing surveillance?

    Evidence Snapshot

    • Regulatory Status: Multiple peptides including BPC-157, TB-500, and Ipamorelin are classified as FDA Category 2 bulk substances (as of September 2023).
    • Compounding Eligibility: Substances under Category 2 (503A) are generally ineligible for routine compounding due to safety risks or lack of clinical-need exemptions.
    • Safety Signals: FAERS data for GLP-1 RAs indicate strong gastrointestinal signals (nausea, vomiting, delayed gastric emptying) and emerging signals for NAION and pulmonary aspiration.
    • Human Trial Data: Phase III evidence exists for approved agents like Semaglutide and Tirzepatide, whereas substances like TB-500 lack human exposure data.
    • Regulatory Action: Warning letters have been issued to multiple entities (e.g., Tailor Made Compounding, Predator Nutrition) regarding the distribution of non-approved peptides.

    What the Research Shows

    FDA Regulatory and Compounding Status

    As of March 2026, the FDA has not approved several widely discussed peptides, including BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, and GHRP-2. The regulatory landscape for these substances changed significantly in September 2023, when many were placed in Category 2 for 503A compounding, indicating significant safety risks or a lack of demonstrated safety data.

    Specific findings include:

    • BPC-157: Classified as a Category 2 bulk substance due to immunogenicity concerns and a lack of safety data. It is ineligible for routine compounding.
    • Thymosin Alpha-1: Although approved in over 35 countries as Zadaxin, it is not FDA-approved. It was moved to Category 2 (503A) in September 2023, and although it was removed pending advisory review in September 2024, it remains a substance of concern under interim policy.
    • CJC-1295 & Ipamorelin: Nominations for these peptides were withdrawn and they were removed from 503A lists in September 2024. For CJC-1295, the FDA specifically cited safety issues such as increased heart rate.
    • TB-500: The FDA cites immunogenicity risks and a complete lack of human exposure data.

    FAERS Safety Signal Analysis

    Postmarketing surveillance for Semaglutide, as of December 2024, shows 187,757 total AE reports for GLP-1 RAs. Strong signals (elevated Relative Reporting Ratio [ROR]) are confirmed for gastrointestinal events including nausea, vomiting, and delayed gastric emptying. The Ozempic label was updated in 2025 to include pulmonary aspiration risk, which may be contributed to by delayed gastric emptying during general anesthesia.

    Emerging signals under evaluation include:

    • NAION (Nonarteritic Anterior Ischemic Optic Neuropathy): 96 cases reported through December 2024; currently under EMA review (initiated January 2025).
    • Intestinal Obstruction/Ileus: Added to labeling postmarketing following emerging signals.
    • Acute Pancreatitis: A moderate signal (elevated Proportional Reporting Ratio [PRR]) resulting in a boxed-adjacent warning.
    • Suicidal Ideation: Currently under FDA monitoring, though data do not support a higher risk versus background rates.

    Clinical Trial Outcomes

    Phase III trials for approved agents demonstrate significant clinical outcomes. The STEP 1 trial (NCT03548935) showed 14.9% weight loss with Semaglutide, while the SELECT trial (NCT03574597) showed a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tirzepatide demonstrated 22.5% weight loss in the SURMOUNT-1 trial (NCT04184622). Conversely, a Phase III trial for Thymosin Alpha-1 in sepsis (NCT02867267) was negative, showing no reduction in mortality.

    Mechanism

    The mechanisms for these substances are not provided in the source records for the listed Category 2 peptides. For Semaglutide, mechanisms relating to delayed gastric emptying are noted as contributing factors to safety signals such as pulmonary aspiration and impact on oral medication absorption.

    Limitations of the Evidence

    The primary limitation for peptides like BPC-157 and TB-500 is the absence of human exposure and safety data. While substances like Selank and Semax are approved in Russia, they lack FDA approval or comprehensive US-based safety evaluations. For emerging safety signals like NAION, the evidence is based on a limited number of cases (96) and is still undergoing formal regulatory review. Many regulatory statuses are based on interim policies and pending advisory reviews, indicating the landscape is subject to change.

    Clinical Takeaway

    Physicians should be aware that the FDA has categorized many non-approved peptides (e.g., BPC-157, TB-500, GHRP-2) as Category 2 bulk substances due to safety risks, including immunogenicity. For approved GLP-1 RAs, clinicians should monitor for gastrointestinal-related dehydration leading to acute kidney injury and emerging risks like NAION and pulmonary aspiration during surgery.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Sources

    • REGULATORY STATUS RECORDS: 0abdad3c, 68b0b103, c8181049, 96fb1240, 1a160b34, 116a4f32, 856316f2, fe228995, a11f0210, a6e75c1b.
    • FAERS SAFETY SIGNALS: 502f8ab5, 0296a263, d2135902, 4f021484, 3c2b6572, bcece5fd, afc343ed, be753983, 99f7d6d6, 60c7beaa.
    • CLINICAL TRIAL RECORDS: 65446b68, 2f6b401e, 91163f2f, c4da06d8, 1b33afa2, 733e7bb7, 081507ec, 55115d78, 61da0d9a, 654eb1d4.

    Referenced Peptides

    bpc 157thymosin alpha 1tb 500semaglutidetirzepatide

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.